B. Braun Indonesia launches the commercial production of infusion solutions in Karawang
B. Braun Indonesia officially commenced the commercial production of its basic infusion solutions at its Karawang factory today. The pharmaceutical manufacturing facility will produce more than one million bottles per month to fully support the needs of Indonesia people for high-quality, yet affordable, infusion solutions products.
The manufacturing facility was officially opened by the Minister of Health of the Republic of Indonesia, Prof. Dr. dr. Nila Djuwita F. Moeloek and Member of the Management Board, B. Braun Melsungen & President of B. Braun Asia Pacific, Ms. Anna Maria Braun on 27 July 2017.
Managing Director of B. Braun Indonesia, Rainer Ruppel, said, “For almost 40 years, B. Braun has strived to protect and improve the health of people in Indonesia and around the world. Today, we continue our commitment to this nation by starting the commercial production of our manufacturing facility in Cikampek, Karawang to provide high quality infusion solutions and services, with great emphasis on process optimization, safety, partnerships and progress.”
B. Braun’s investment in this manufacturing facility is in line with the Presidential Instruction No. 6 of 2016 on Acceleration of Pharmaceutical Industry and Medical Instruments and the Minister of Health Regulation No. 17/2017 on the Action Plan for the Development of Pharmaceutical and Medical Devices in Indonesia. With the commencement of commercial production at this B. Braun facility, Indonesia will be able to minimize its dependency on imported products, capable of anticipating medicinal shortages, as well as become an exporter of high quality infusion solutions to the region in future.
Built on an area of 19 hectares with an investment value more than IDR 1 trillion, the facility features the latest building and production technologies and was certified by the Drug Supervisory Agency of Indonesia (Badan Pengawas Obat dan Makanan/ BPOM) on 30 January 2018. The annual production capacity shall reach 15 million units in the first phase and 50 million units in the second phase. This state-of-the-art facility manufactures Ecosol Ringer Lactate, Ecosol Sodium Chloride 0.9%, Ecosol Glucose 5%, Ecosol Glucose 10%, Ecosol Glucose 5% & Sodium Chloride 0.9%, Ecosol Water for Injection, and Sterofundin ISO.
With 62,000 employees in 64 countries, B. Braun is a leading global healthcare company specializing in solutions related to infusion therapy, orthopaedics, neurosurgery, anaesthesia, extracorporeal blood treatment, spine surgery, diabetes care, clinical nutrition, wound management, infection prevention and surgical technologies. In 2017, B. Braun achieved third-party sales of 6.78 billion Euros.
In Indonesia, B. Braun owns two legal entities, which are B. Braun Medical Indonesia, the country office in Jakarta; and B. Braun Pharmaceutical Indonesia, its manufacturing site in Karawang, West Java. B. Braun Medical Indonesia is involved in the marketing and distributing of medical devices and pharmaceutical products. Its sales offices are present throughout the country and it prides itself on playing a key role in educating and training healthcare professionals in keeping with its vision to improve healthcare throughout Indonesia.
For more information, please visit www.bbraun.com